Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk
Authors:
Open Access
- 7 May 2009
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 265 (6) , 653-662
Abstract
: One of the strongest associations with autoantibodies directed to components of the SSA/Ro‐SSB/La ribonucleoprotein complex is the development of congenital heart block (CHB) in an offspring, an alarming prospect facing 2% of primigravid mothers with these reactivities. This risk is 10‐fold higher in women who have had a previously affected child with CHB. Anti‐Ro/La antibodies are necessary but insufficient to cause disease. In vitro and in vivo experiments suggest that the pathogenesis involves exaggerated apoptosis, macrophage/myfibroblast crosstalk, TGFβ expression and extensive fibrosis in the conducting system and in some cases surrounding myocardium. A disturbing observation is the rapidity of disease progression, with advanced heart block and life‐threatening cardiomyopathy observed <2 weeks from normal sinus rhythm. Once 3rd degree (complete) block is identified, reversal has never been achieved, despite dexamethasone. Current strategies include the evaluation of an early echocardiographic marker of injury, such as a prolonged PR interval and the use of IVIG as a preventative measure for pregnancies of mothers with previously affected children.Keywords
This publication has 34 references indexed in Scilit:
- Antibody Reactivity to α-Enolase in Mothers of Children with Congenital Heart BlockThe Journal of Rheumatology, 2009
- Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart BlockCirculation, 2008
- Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: Implications for progression to scarring in autoimmune‐associated congenital heart blockArthritis & Rheumatism, 2007
- The antiinflammatory activity of IgG: the intravenous IgG paradoxJournal of Experimental Medicine, 2007
- Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart blockJournal of Clinical Investigation, 2006
- Maternal antibody responses to the 52‐kd SSA/RO p200 peptide and the development of fetal conduction defectsArthritis & Rheumatism, 2005
- Structurally Derived Mutations Define Congenital Heart Block‐Related Epitopes Within the 200–239 Amino Acid Stretch of the Ro52 ProteinScandinavian Journal of Immunology, 2005
- Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: Comment on the editorial by Buyon et alArthritis & Rheumatism, 2003
- Isolated congenital heart block. long‐term outcome of mothers and characterization of the immune response to ss‐a/ro and to ss‐b/laArthritis & Rheumatism, 1993
- Postnatal progression from second- to third-degree heart block in neonatal lupus syndromeThe Journal of Pediatrics, 1988